Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent
Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, X. C, Lapi SE. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. Oncotarget 2017, 5: 104303-104314. PMID: 29262642, PMCID: PMC5732808, DOI: 10.18632/oncotarget.22228.Peer-Reviewed Original ResearchTriple-negative breast cancerMDA-MB-468 xenograftsNegative breast cancerCDX-011Breast cancerMean SUVTumor uptakePatient-derived xenograft modelsDiagnostic imaging agentsGPNMB expressionMDA-MB-231 tumorsSelection of patientsTNBC cell linesImaging agentGlembatumumab vedotinPDX micePharmacologic propertiesPreclinical studiesXenograft modelTargeted treatmentMelanoma BDays p.Preclinical PET imagingUptake correlatesEffective dose